This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Clinicaltrials are expensive, slow and often limited by outdated design constraints. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data. Accelerating timelines and de-risking development decisions across the pipeline.”
Advanced strategies and tools are being implemented to establish the safety and efficacy of new therapeutic modalities, with the development of new biomarkers becoming one of the most relevant approaches for enhancing the precision and utility of early-stage studies.
As clinicaltrials become increasingly complex, particularly in decentralized trials and rare disease studies, sponsors experience increased challenges in site selection, forecasting and resourcing, and patient recruitment and enrollment. Discover how AI is used to optimize key aspects of clinicaltrial management.
Discovered by Daiichi Sankyo, I-DXd is being co-developed with Merck (known as MSD outside of North America) as part of a broader strategic collaboration between the two companies. Addressing a Pressing Clinical Need in Prostate Cancer Prostate cancer remains one of the most prevalent malignancies among men worldwide.
Zylberberg has built an impressive career at the intersection of science, technology, and business. It involves a dynamic and often unpredictable process where every stage, from target identification to clinicaltrials, generates vast amounts of data. Personalised AI solutions, however, are transforming this landscape.
In just two years, CTMC has advanced eight therapies into clinicaltrials, harnessing genetic engineering to enhance T-cell effectiveness in the fight against cancer. Ive been involved in therapeutics development for over 25 years, working with small, medium, and large biotech companies.
The complexity of diagnosing IPF, understanding its root causes, and translating preclinical findings to clinical success make it a challenging disease for drug development. However, recent advancements and strategic approaches in clinicaltrials offer hope that additional treatments are on the way.
Clinical genomics, powered by NGS, enables more precise target validation, improved patient stratification and optimised trial design, ultimately aiming to increase PoS. For example, MLMs can simultaneously explore genetic sequences and clinical data to improve crucial characteristics such as efficacy, safety and bioavailability.
“Protocol development can be a complex and meticulous process,” he explains, “as it’s crucial to ensure that trial candidates meet the necessary inclusion criteria.” Prior treatments and patient histories often introduce variables that can affect outcomes, making thoughtful trial design essential for generating reliable data.
Amelie Croset, Senior Director of Alliances and Partnering at the therapeutics company Molecular Partners, spoke with Drug Target Review about the science behind the presentation posters, its therapeutic potential and what is next for the platform. ” From there, things moved fast. ” And what a year to make the switch. .
In March 2025 , Regulus announced the successful completion of its Phase 1b multiple-ascending dose clinicaltrial for farabursen. The development of farabursen is expected to move into Phase 2 clinicaltrials in the second half of 2025, pending regulatory clearance.
The results from the Phase I/II NXTAGE trial, announced during the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C., The trial is evaluating NXT007 in people with hemophilia A without factor VIII inhibitors who have not previously been treated with Hemlibra.
Through this transaction, Revolution Medicines maintains full ownership and executional control over its clinical programs and commercial strategy in the U.S. Early data has demonstrated encouraging signs of efficacy and safety, and the company is planning to initiate pivotal trials in the near term.
Predictability of in vitro to in vivo metabolism Predictivity varies but the top line from the responses is that the probability of discovering a major metabolite during later stages of clinicaldevelopment are low, as is complete discordance of in vitro to in vivo metabolism. Paper Savaryn, J.P., Cerny, M.A.
It provides a range of incentives to the sponsoring company, including seven years of market exclusivity upon approval, tax credits for clinicaltrial costs, fee waivers, and eligibility for expedited regulatory pathways. VITALIZE (NCT06290141): Evaluates the drug in CIDP patients currently receiving intravenous immunoglobulin (IVIg).
Our goals are to progress our pipeline and position each asset for clinical and commercial success. The tight-knit structure of the Poolbeg team allows Tremble to contribute not only to early-stage drug development but also to clinicaltrial design, patient stratification, and biomarker strategy.
As part of the extended agreement, Bayer will continue to provide funding, technical support, and strategic guidance for joint projects, while also offering resources and recognition to Tsinghua’s scientists who are driving forward life sciences innovation.
He has contributed to more than 130 granted patents and advanced over 12 clinical drug candidates across various therapeutic areas, including cognition, depression, pain and other disorders. With over 25 years of experience in the pharmaceutical industry, Donello has been instrumental in drug discovery and development.
Balancing generative AI opportunities and risks Generative AI offers unparalleled opportunities for transforming various aspects of health care and clinical research. In clinicaltrials, generative AI accelerates trial designs through protocol optimization and enrollment forecasting, leading to faster and more effective studies.
Founded in 1975 by Shin Ashida, who continues to serve as Chairman, President, and CEO, JCR began as a small research-driven company rooted in the pursuit of cutting-edge science. At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,” said Mr. Ashida. “In
Grifols’ BT524 Fibrinogen Therapy Shows Promise in Phase 3 Trial Published in The Lancet’s eClinicalMedicine Grifols , a globally recognized healthcare company and a leader in the production of plasma-derived therapies, has marked a significant advancement in the treatment of acquired fibrinogen deficiency (AFD).
With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drug developers with the tools, insights, and support needed to advance their therapies from concept to clinic. Meet Daniel Galbraith Dr Daniel Galbraith is an innovation driver and science leader in the Biotechnology Industry.
This strategic collaboration aims to enable the continued clinicaldevelopment and eventual delivery of a low-cost, effective Shigella vaccine to children in low- and middle-income countries (LMICs), where the disease’s health impact is most severe.
In an era where science and technology are surpassing what was ever thought possible, the need for the biotech industry to adapt, respond and evolve as quickly and cost efficiently as possible is more urgent than ever. 1 These numbers explain why so many promising biotech firms close their doors each year.
The drug’s clearance came after an unusual clinicaldevelopment journey and, in the ensuing months, has swelled Soleno’s market value past $4 billion amid optimism about the drug’s sales prospects. You can unsubscribe at anytime. Condulis, for instance, predicts Vykat could reach $2.5 billion in worldwide yearly sales at its peak.
Published June 24, 2025 Gwendolyn Wu Senior reporter post share post print email license Lexeo Therapeutics and two life sciences investors are working together to launch a startup to develop cardiac RNA therapies. Nolan Townsend said will help “realize the therapeutic and economic value of promising preclinical science.”
This expansion is creating opportunities for clinicaltrials related to a range of new therapy areas and their subpopulations. The SELECT trial set out to understand whether the drug has similar effect on patients without diabetes.
Based on an analysis of recent Pitchbook data, I estimate >$55B in dry powder (largely for private deals) across >200 life sciences VCs in the U.S. We are likely to continue to see capital skew towards the latter type of deal, with concentration in clinical-stage, asset-centric plays. Is something not resonating?
With significant validation of our platform in hand, we are now rapidly advancing towards the clinic with our lead therapeutic, OSK. We hope to initiate the first human clinicaltrials with our lead indications in 2025, which would represent a monumental step forward for the field of cellular rejuvenation.
Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. Moreover, these delays impact getting potentially lifesaving therapies to patients in need.
Written by Natalia Muehlemann, Vice President, ClinicalDevelopment, and Ari Brettman, Senior Managing Director, Blackstone Life Sciences When working with investors, it’s critical that drug and device developers consider how their clinicaltrial design aligns with investment priorities.
Clissold — The trio of CDER, CBER, and CDRH released a new draft guidance titled “ Use of Data Monitoring Committees in ClinicalTrials ” that revises the 2006 guidance “Establishment and Operation of ClinicalTrial Data Monitoring Committees” and, when final, will replace the 2006 guidance.
Our dedicated, global and highly experienced cross-functional early development team is ready to support you through this journey. The partner you select for your early phase studies is critical in enabling you to achieve your overall development timeline efficiently and within budget.
By: Sarah Bly and Aman Khera, Regulatory Science and Innovation The journey of bringing a new therapeutic agent from the laboratory to the marketplace is fraught with challenges, not least of which is navigating the complexities of regulatory feedback, which do not always converge but can diverge.
Top 10 Life Science Resources pmjackson Mon, 10/30/2023 - 16:16 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for you. Catch up on what you may have missed below! Read it now. The Altascientist : Issue No.
Originally developed in the 1970s to treat diabetes, these drugs—such as Ozempic, Wegovy, and Mounjaro—have become headline-makers for their ability to induce significant weight loss. You can unsubscribe at anytime. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.s
You may have heard that our clinicaltrial strategy platform Solara® won the Fierce Life Sciences award for Technology Innovation , so let’s take a closer look at simulation-guided design and what it enables clinicaltrial sponsors to do.
and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinicaldevelopment programme. For further information please visit www.gsk.com/about-us.
Prior to joining Gannex, Dr. Palmer was Head of Liver Disease ClinicalDevelopment at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. ” About Ascletis.
This program will encourage therapeutic sponsors to communicate with FDA officials more regularly and as needed to improve their clinicaldevelopment of gene- and cell-based therapies. Read the Article The post #ScienceSaturday: September 30, 2023 appeared first on KIF1A.
Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. Communication and networking are key in any career, with science being no exception.
15, 2020– Gilead Sciences, Inc. Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The trial met its primary endpoint by demonstrating that in people with NASH and mild to moderate fibrosis all regimens were well tolerated. About Gilead Sciences.
Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinicaltrial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. That is, how many clinicaltrials are actually managed by these organizations?
As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drug development shaped the pharma and biotech industries. These shifts are a prelude to further change and progress in the clinicaltrial landscape in 2024. Five Predictions for the Drug Development Industry in 2024 1.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content